<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35550514</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2373-8057</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>NPJ Parkinson's disease</Title>
          <ISOAbbreviation>NPJ Parkinsons Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuropathology of Parkinson's disease after focused ultrasound thalamotomy.</ArticleTitle>
        <Pagination>
          <StartPage>59</StartPage>
          <MedlinePgn>59</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">59</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41531-022-00319-6</ELocationID>
        <Abstract>
          <AbstractText>Focused ultrasound (FUS) thalamotomy is an emerging treatment for tremor-dominant Parkinson's disease (PD). We report the first postmortem neuropathologic study of FUS thalamotomy in a 68-year-old man with tremor-dominant PD, which was performed seven months before he died. Although the peak voxel temperature at the target was &lt;54 °C, his tremor improved on intraoperative and postoperative assessments. Additionally, postoperative MRI demonstrated a thalamic lesion. Lewy body-related pathology consistent with PD was detected. There was also a 5-mm lesion in the ventral lateral thalamus characterized by demyelination and neuropil loss, with many lipid-laden macrophages, but no lymphocytic infiltrates and relatively preserved neurons and axons. Additional pathological assessments after FUS thalamotomy are needed to determine if the observed brain changes are typical of this procedure.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Koga</LastName>
            <ForeName>Shunsuke</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8868-9700</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishaque</LastName>
            <ForeName>Mariam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, University of Virginia Health Science Center, Charlottesville, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeffrey Elias</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, University of Virginia Health Science Center, Charlottesville, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Binit B</ForeName>
            <Initials>BB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, University of Virginia Health Science Center, Charlottesville, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murakami</LastName>
            <ForeName>Aya</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dickson</LastName>
            <ForeName>Dennis W</ForeName>
            <Initials>DW</Initials>
            <Identifier Source="ORCID">0000-0001-7189-7917</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FI, USA. dickson.dennis@mayo.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>NPJ Parkinsons Dis</MedlineTA>
        <NlmUniqueID>101675390</NlmUniqueID>
        <ISSNLinking>2373-8057</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>S.K., M.I., B.B.S., A.M., and D.W.D. declare no competing interests. W.J.E. serves as a consultant for InSightec LTD.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35550514</ArticleId>
        <ArticleId IdType="pmc">PMC9098516</ArticleId>
        <ArticleId IdType="doi">10.1038/s41531-022-00319-6</ArticleId>
        <ArticleId IdType="pii">10.1038/s41531-022-00319-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Postuma RB, et al.  MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26424</ArticleId>
            <ArticleId IdType="pubmed">26474316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozano AM, et al.  Deep brain stimulation: current challenges and future directions. Nat. Rev. Neurol. 2019;15:148–160. doi: 10.1038/s41582-018-0128-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-018-0128-2</ArticleId>
            <ArticleId IdType="pmc">PMC6397644</ArticleId>
            <ArticleId IdType="pubmed">30683913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel DM, et al.  Adverse events associated with deep brain stimulation for movement disorders: analysis of 510 consecutive cases. Neurosurgery. 2015;11(Suppl. 2):190–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25599204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachenmayer ML, et al.  Subthalamic and pallidal deep brain stimulation for Parkinson’s disease-meta-analysis of outcomes. NPJ Parkinsons Dis. 2021;7:77. doi: 10.1038/s41531-021-00223-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41531-021-00223-5</ArticleId>
            <ArticleId IdType="pmc">PMC8421387</ArticleId>
            <ArticleId IdType="pubmed">34489472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Y, Hynynen K, Lipsman N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat. Rev. Neurol. 2021;17:7–22. doi: 10.1038/s41582-020-00418-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-00418-z</ArticleId>
            <ArticleId IdType="pubmed">33106619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elias WJ, et al.  A pilot study of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 2013;369:640–648. doi: 10.1056/NEJMoa1300962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1300962</ArticleId>
            <ArticleId IdType="pubmed">23944301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park YS, Jung NY, Na YC, Chang JW. Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov. Disord. 2019;34:727–734. doi: 10.1002/mds.27637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.27637</ArticleId>
            <ArticleId IdType="pubmed">30759322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elias WJ, et al.  A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 2016;375:730–739. doi: 10.1056/NEJMoa1600159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1600159</ArticleId>
            <ArticleId IdType="pubmed">27557301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bond AE, et al.  Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74:1412–1418. doi: 10.1001/jamaneurol.2017.3098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2017.3098</ArticleId>
            <ArticleId IdType="pmc">PMC5822192</ArticleId>
            <ArticleId IdType="pubmed">29084313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenberg, H. M. et al. MR-guided focused ultrasound pallidotomy for Parkinson’s disease: safety and feasibility. J Neurosurg. 1–7 10.3171/2020.6.JNS192773 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Wintermark M, et al.  Imaging findings in MR imaging-guided focused ultrasound treatment for patients with essential tremor. Am. J. Neuroradiol. 2014;35:891–896. doi: 10.3174/ajnr.A3808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A3808</ArticleId>
            <ArticleId IdType="pmc">PMC7964546</ArticleId>
            <ArticleId IdType="pubmed">24371027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harary M, Essayed WI, Valdes PA, McDannold N, Cosgrove GR. Volumetric analysis of magnetic resonance-guided focused ultrasound thalamotomy lesions. Neurosurg. Focus. 2018;44:E6. doi: 10.3171/2017.11.FOCUS17587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2017.11.FOCUS17587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elias WJ, et al.  A magnetic resonance imaging, histological, and dose modeling comparison of focused ultrasound, radiofrequency, and Gamma Knife radiosurgery lesions in swine thalamus. J. Neurosurg. 2013;119:307–317. doi: 10.3171/2013.5.JNS122327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2013.5.JNS122327</ArticleId>
            <ArticleId IdType="pubmed">23746105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, et al.  Intracranial inertial cavitation threshold and thermal ablation lesion creation using MRI-guided 220-kHz focused ultrasound surgery: preclinical investigation. J. Neurosurg. 2015;122:152–161. doi: 10.3171/2014.9.JNS14541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2014.9.JNS14541</ArticleId>
            <ArticleId IdType="pubmed">25380106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker MR, et al.  Acute MR-guided high-intensity focused ultrasound lesion assessment using diffusion-weighted imaging and histological analysis. Front. Neurol. 2019;10:1069. doi: 10.3389/fneur.2019.01069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.01069</ArticleId>
            <ArticleId IdType="pmc">PMC6803785</ArticleId>
            <ArticleId IdType="pubmed">31681145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Fernandez R, et al.  Randomized trial of focused ultrasound subthalamotomy for Parkinson’s disease. N. Engl. J. Med. 2020;383:2501–2513. doi: 10.1056/NEJMoa2016311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2016311</ArticleId>
            <ArticleId IdType="pubmed">33369354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickson DW, et al.  Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150–1157. doi: 10.1016/S1474-4422(09)70238-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70238-8</ArticleId>
            <ArticleId IdType="pubmed">19909913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung, N. Y. et al. The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson’s disease: a Phase I clinical trial. J. Neurosurg. 1–9 10.3171/2018.2.JNS172514 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Yang AI, et al.  Patient-specific effects on sonication heating efficiency during magnetic resonance-guided focused ultrasound thalamotomy. Med. Phys. 2021;48:6588–6596. doi: 10.1002/mp.15239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mp.15239</ArticleId>
            <ArticleId IdType="pubmed">34532858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson DN, Barnett Y, Kyle K, Tisch S, Jonker BP. Predictors of thermal response and lesion size in patients undergoing magnetic resonance-guided focused ultrasound thalamotomy. J. Clin. Neurosci. 2021;91:75–79. doi: 10.1016/j.jocn.2021.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2021.06.019</ArticleId>
            <ArticleId IdType="pubmed">34373062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang WS, et al.  Factors associated with successful magnetic resonance-guided focused ultrasound treatment: efficiency of acoustic energy delivery through the skull. J. Neurosurg. 2016;124:411–416. doi: 10.3171/2015.3.JNS142592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.3.JNS142592</ArticleId>
            <ArticleId IdType="pubmed">26361280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, M. J. et al. Technical and operative factors affecting magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor: experience from 250 treatments. J. Neurosurg. 1–9 10.3171/2020.11.JNS202580 (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Fry WJ, Barnard JW, Fry EJ, Krumins RF, Brennan JF. Ultrasonic lesions in the mammalian central nervous system. Science. 1955;122:517–518. doi: 10.1126/science.122.3168.517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.122.3168.517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasano A, et al.  MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology. 2017;89:771–775. doi: 10.1212/WNL.0000000000004268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004268</ArticleId>
            <ArticleId IdType="pubmed">28747452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto K, et al.  Focused ultrasound thalamotomy for tremor-dominant Parkinson’s disease: a prospective 1-year follow-up study. Neurol. Med. Chir. 2021;61:414–421. doi: 10.2176/nmc.oa.2020-0370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.oa.2020-0370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang TR, et al.  Transcranial magnetic resonance imaging-guided focused ultrasound thalamotomy for tremor: technical note. Neurosurg. Focus. 2018;44:E3. doi: 10.3171/2017.10.FOCUS17609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2017.10.FOCUS17609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–1800. doi: 10.1212/WNL.58.12.1791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId>
            <ArticleId IdType="pubmed">12084879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. doi: 10.1007/BF00308809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00308809</ArticleId>
            <ArticleId IdType="pubmed">1759558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montine TJ, et al.  National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123:1–11. doi: 10.1007/s00401-011-0910-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId>
            <ArticleId IdType="pmc">PMC3268003</ArticleId>
            <ArticleId IdType="pubmed">22101365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koga, S., Zhou, X. &amp; Dickson, D. W. Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. Neuropathol. Appl Neurobiol. 10.1111/nan.12710 (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Dickson DW, et al.  Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 1999;155:1241–1251. doi: 10.1016/S0002-9440(10)65226-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)65226-1</ArticleId>
            <ArticleId IdType="pmc">PMC1867032</ArticleId>
            <ArticleId IdType="pubmed">10514406</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
